Veru is trading 5.65% down now at $2.61, with no confirmed catalyst identified for the August 11 pre-market decline.
- Veru gained 18.88% to $2.77 on August 10.
- The company reported a narrower fiscal third-quarter loss of $0.30 per share.
- PLATEAU fully enrolled 239 patients, with interim results expected in the first quarter of 2027. Profit-taking remains unconfirmed.